Spero Therapeutics Inc (SPRO)

09:07 AM

Spero Therapeutics Inc (SPRO) Q1 2025: Everything You Need To Kn - GuruFocus

09:07 AM

May 07, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Bought by JPMorgan Chase & Co. - Defense World

May 07, 2025

May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - The Manila Times

May 05, 2025

May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire

May 05, 2025

May 05, 2025

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update ... - Eagle-Tribune

May 05, 2025

May 05, 2025

Spero Therapeutics Confirms Q1 Earnings Date: Latest Updates on Rare Disease and MDR Programs Coming May 13 - Stock Titan

May 05, 2025

Apr 30, 2025

Renaissance Technologies LLC Increases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 30, 2025

Apr 28, 2025

Spero Therapeutics Appoints Esther Rajavelu as CEO - citybiz

Apr 28, 2025

Apr 28, 2025

New Leadership Announcement for Spero Therapeutics (SPRO) | SPRO Stock News - GuruFocus

Apr 28, 2025

Apr 28, 2025

Spero Therapeutics appoints new CEO and board nominee - Investing.com

Apr 28, 2025

Apr 28, 2025

Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer - marketscreener.com

Apr 28, 2025

Apr 28, 2025

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer - GlobeNewswire

Apr 28, 2025

Apr 28, 2025

Spero Therapeutics Promotes CFO to CEO Role as Critical Phase 3 Trial Results Approach - Stock Titan

Apr 28, 2025

Apr 26, 2025

Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Apr 26, 2025

Apr 12, 2025

Prudential Financial Inc. Acquires Shares of 49,200 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 12, 2025

Apr 09, 2025

Spero Therapeutics stock hits 52-week low at $0.51 amid challenges - Investing.com Canada

Apr 09, 2025

Apr 09, 2025

Spero Therapeutics stock hits 52-week low at $0.51 amid challenges By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 07, 2025

Bronstein, Gewirtz & Grossman, LLC Notifies Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire

Apr 07, 2025

Apr 05, 2025

Spero Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc. - MarketScreener

Apr 05, 2025

Apr 02, 2025

Virtu Financial LLC Makes New $47,000 Investment in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 02, 2025

Mar 29, 2025

We're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate - Yahoo Finance

Mar 29, 2025

Mar 28, 2025

Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast - Investing.com India

Mar 28, 2025

Mar 28, 2025

Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: - GuruFocus

Mar 28, 2025

Mar 27, 2025

Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

Spero Therapeutics earnings missed by $0.02, revenue topped estimates - Investing.com Canada

Mar 27, 2025

Mar 27, 2025

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 27, 2025

Mar 27, 2025

Spero Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

SPERO THERAPEUTICS Earnings Results: $SPRO Reports Quarterly Earnings - Nasdaq

Mar 27, 2025

Mar 27, 2025

Spero Q4 Earnings: $68.6M Loss, Pipeline Setbacks, and New Interim CEO Named - Stock Titan

Mar 27, 2025

Mar 26, 2025

A Glimpse of Spero Therapeutics's Earnings Potential - Benzinga

Mar 26, 2025

Mar 25, 2025

Spero Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView

Mar 25, 2025

Mar 25, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World

Mar 25, 2025

Mar 19, 2025

Spero Therapeutics to Report Fourth Quarter and Full Year - GlobeNewswire

Mar 19, 2025

Mar 18, 2025

Spero Therapeutics Q4 Earnings: Rare Disease Pipeline and Financial Results Coming March 27 - StockTitan

Mar 18, 2025

Mar 14, 2025

Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - The AM Reporter

Mar 14, 2025

Mar 11, 2025

Spero Therapeutics stock hits 52-week low at $0.74 amid challenges - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Spero Therapeutics stock hits 52-week low at $0.74 amid challenges By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 10, 2025

Spero Therapeutics (SPRO) Projected to Post Earnings on Wednesday - The AM Reporter

Mar 10, 2025

Mar 05, 2025

Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Wednesday - Defense World

Mar 05, 2025

Mar 04, 2025

Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart

Mar 04, 2025

Mar 03, 2025

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 03, 2025

Mar 01, 2025

Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN

Mar 01, 2025

Mar 01, 2025

Spero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia

Mar 01, 2025

Mar 01, 2025

Spero Therapeutics faces Nasdaq delisting over share price - Investing.com India

Mar 01, 2025